improvements in lipid panel is indicative of efficacy
measure serum lipid values (ie, total cholesterol, triglycerides, and LDL-C) for response to therapy [1]
creatinine kinase levels, in patients predisposed to rhabdomyolysis (eg, elderly, females, renal impairment, hypoalbuminemia, uncontrolled hypothyroidism, alcohol abuse, or personal or familial history of hereditary muscular disorders); prior to treatment; remeasure within 5 to 7 days if significantly elevated [1]
creatine phosphokinase levels; baseline and during treatment [1]
transaminase levels; prior to treatment, every 3 months during the first 12 months of treatment, and periodically thereafter [1]
creatinine; during the first 3 months of treatment and periodically thereafter [1]
biochemical and clinical parameters of diabetes, in patients at risk; according to national guidelines [1]